Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
YANTAI, China, May 12, 2025 /PRNewswire/ — On May 12th, 2025, RemeGen…
Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types – with Special Focus on the Brain
HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ — A groundbreaking international study has…